✦ LIBER ✦

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

✍ Scribed by Saad, F.; Brown, J. E.; Van Poznak, C.; Ibrahim, T.; Stemmer, S. M.; Stopeck, A. T.; Diel, I. J.; Takahashi, S.; Shore, N.; Henry, D. H.; Barrios, C. H.; Facon, T.; Senecal, F.; Fizazi, K.; Zhou, L.; Daniels, A.; Carriere, P.; Dansey, R.

Book ID: 125449275
Publisher: Oxford University Press
Year: 2012
Tongue: English
Weight: 197 KB
Volume: 23
Category: Article
ISSN: 0923-7534
DOI: 10.1093/annonc/mdr435

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Incidence and outcomes of osteonecrosis

Incidence and outcomes of osteonecrosis of the jaw from an integrated analysis of three pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab and zoledronic acid for treatment of bone metastases in advanced cancer patients or myeloma

✍ J.E. Brown*; C.H. Barrios; I.J. Diel; T. Facon; K. Fizazi; T. Ibrahim; F. Saad; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Final safety and efficacy analysis of th

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial

✍ Nicholas D. James; Armelle Caty; Heather Payne; Michael Borre; Bernard A. Zonnen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB

Ustekinumab, an anti-IL-12/23 p40 monocl

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

✍ Kavanaugh, Arthur (author);Ritchlin, Christopher (author);Rahman, Proton (author 📂 Article 📅 2014 🏛 BMJ Publishing Group 🌐 English ⚖ 984 KB

Ustekinumab, an anti-IL-12/23 p40 monocl

✍ Kavanaugh, Arthur (author);Ritchlin, Christopher (author);Rahman, Proton (author 📂 Article 📅 2014 🏛 BMJ Publishing Group 🌐 English ⚖ 984 KB